Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$0.21 - $5.63 $32,697 - $876,607
155,703 Added 277.5%
211,812 $54,000
Q3 2022

Nov 14, 2022

SELL
$0.46 - $6.75 $29,255 - $429,286
-63,598 Reduced 53.13%
56,109 $23,000
Q2 2022

Aug 15, 2022

BUY
$0.27 - $0.61 $20,495 - $46,303
75,908 Added 173.31%
119,707 $61,000
Q1 2022

May 16, 2022

SELL
$0.5 - $0.88 $2,085 - $3,669
-4,170 Reduced 8.69%
43,799 $26,000
Q4 2021

Feb 14, 2022

SELL
$0.58 - $1.09 $12,030 - $22,608
-20,742 Reduced 30.19%
47,969 $28,000
Q3 2021

Nov 15, 2021

SELL
$0.93 - $1.18 $39,946 - $50,684
-42,953 Reduced 38.47%
68,711 $78,000
Q2 2021

Aug 16, 2021

BUY
$1.19 - $2.06 $107,610 - $186,283
90,429 Added 425.85%
111,664 $133,000
Q1 2021

May 17, 2021

BUY
$1.62 - $3.05 $5,389 - $10,147
3,327 Added 18.58%
21,235 $44,000
Q4 2020

Feb 16, 2021

SELL
$1.44 - $1.98 $16,819 - $23,126
-11,680 Reduced 39.48%
17,908 $28,000
Q3 2020

Nov 16, 2020

BUY
$0.8 - $2.33 $13,156 - $38,319
16,446 Added 125.14%
29,588 $51,000
Q2 2020

Aug 14, 2020

SELL
$0.75 - $1.29 $10,511 - $18,079
-14,015 Reduced 51.61%
13,142 $11,000
Q1 2020

May 14, 2020

SELL
$0.33 - $1.62 $2,515 - $12,350
-7,624 Reduced 21.92%
27,157 $26,000
Q4 2019

Feb 14, 2020

BUY
$1.23 - $2.67 $42,780 - $92,865
34,781 New
34,781 $55,000
Q2 2019

Aug 14, 2019

SELL
$1.65 - $6.72 $19,912 - $81,096
-12,068 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$4.84 - $9.07 $58,409 - $109,456
12,068 New
12,068 $84,000
Q4 2018

Feb 14, 2019

SELL
$4.21 - $14.28 $95,238 - $323,042
-22,622 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$13.02 - $17.54 $276,453 - $372,426
-21,233 Reduced 48.42%
22,622 $317,000
Q2 2018

Aug 14, 2018

BUY
$16.51 - $19.85 $724,046 - $870,521
43,855 New
43,855 $724,000

Others Institutions Holding ECOR

About electroCore, Inc.


  • Ticker ECOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 71,176,896
  • Market Cap $1.12B
  • Description
  • electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults....
More about ECOR
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.